Wedbush Starts NovoCure Ltd. (NVCR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Novocure Reports Third Quarter 2015 Operating and Financial Results
October 26, 2015 4:05 PM EDTFDA approved Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015
CE Mark was placed on the second generation Optune system. First patients treated in Europe with the newly designed, smaller, lighter system
468 active patients at quarter end, an increase of 161% versus the prior year quarter end
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported operating and financial results for the three and nine months ended September 30, 2015.
... More
